Gladius Capital Management LP Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)

Gladius Capital Management LP purchased a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the third quarter, according to its most recent filing with the SEC. The firm purchased 3,009 shares of the company’s stock, valued at approximately $35,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. nVerses Capital LLC purchased a new stake in Roivant Sciences during the second quarter valued at approximately $34,000. US Bancorp DE boosted its position in shares of Roivant Sciences by 146.5% in the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after purchasing an additional 1,948 shares in the last quarter. Point72 Hong Kong Ltd purchased a new position in Roivant Sciences during the 2nd quarter worth $36,000. Quarry LP acquired a new position in Roivant Sciences during the 2nd quarter valued at about $53,000. Finally, Acadian Asset Management LLC purchased a new stake in Roivant Sciences in the first quarter valued at about $72,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Stock Down 3.8 %

Shares of Roivant Sciences stock opened at $11.20 on Friday. The firm has a market cap of $8.28 billion, a PE ratio of 1.98 and a beta of 1.24. Roivant Sciences Ltd. has a twelve month low of $8.56 and a twelve month high of $13.06. The business has a 50-day moving average price of $11.75 and a 200 day moving average price of $11.32.

Analyst Ratings Changes

Several research firms have recently commented on ROIV. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Finally, Bank of America boosted their price target on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.93.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the stock in a transaction on Monday, October 21st. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now directly owns 617,470 shares of the company’s stock, valued at $7,193,525.50. This trade represents a 13.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Keith S. Manchester sold 368,052 shares of the company’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $11.62, for a total transaction of $4,276,764.24. Following the transaction, the director now owns 1,412,126 shares of the company’s stock, valued at approximately $16,408,904.12. This trade represents a 20.68 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,577,309 shares of company stock valued at $42,151,184. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.